Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 3
2008 2
2012 2
2013 4
2014 1
2015 10
2016 8
2017 13
2018 16
2019 11
2020 5
2021 25
2022 15
2023 14
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic options in VEXAS syndrome: insights from a retrospective series.
Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC, Barraco F, Sève P, Jamilloux Y, Sujobert P. Bourbon E, et al. Among authors: sujobert p. Blood. 2021 Jul 1;137(26):3682-3684. doi: 10.1182/blood.2020010177. Blood. 2021. PMID: 33619558 Free article. Review. No abstract available.
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, Coelho H, Fossard G, Barraco F, Galicier L, Bienvenu B, Hirsch P, Vial G, Boutin AB, Galland J, Le Guenno G, Bigot A, Warrington KJ, Kermani TA, Grayson PC, Patel BA, Beck DB, Jamilloux Y, Fenaux P, Sujobert P. Heiblig M, et al. Among authors: sujobert p. Blood. 2022 Aug 25;140(8):927-931. doi: 10.1182/blood.2022016642. Blood. 2022. PMID: 35609174 Free PMC article.
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.
Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, Lacombe V, Terriou L, Ardois S, Bouaziz JD, Mathian A, Le Guenno G, Aouba A, Outh R, Meyer A, Roux-Sauvat M, Ebbo M, Zhao LP, Bigot A, Jamilloux Y, Guillotin V, Flamarion E, Henneton P, Vial G, Jachiet V, Rossignol J, Vinzio S, Weitten T, Vinit J, Deligny C, Humbert S, Samson M, Magy-Bertrand N, Moulinet T, Bourguiba R, Hanslik T, Bachmeyer C, Sebert M, Kostine M, Bienvenu B, Biscay P, Liozon E, Sailler L, Chasset F, Audemard-Verger A, Duroyon E, Sarrabay G, Borlot F, Dieval C, Cluzeau T, Marianetti P, Lobbes H, Boursier G, Gerfaud-Valentin M, Jeannel J, Servettaz A, Audia S, Larue M, Henriot B, Faucher B, Graveleau J, de Sainte Marie B, Galland J, Bouillet L, Arnaud C, Ades L, Carrat F, Hirsch P, Fenaux P, Fain O, Sujobert P, Kosmider O, Mekinian A; French VEXAS group; GFEV, GFM, CEREMAIA, MINHEMON. Georgin-Lavialle S, et al. Among authors: sujobert p. Br J Dermatol. 2022 Mar;186(3):564-574. doi: 10.1111/bjd.20805. Epub 2021 Nov 28. Br J Dermatol. 2022. PMID: 34632574 Free article.
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia.
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I, Heiblig M, Boet E, Sahal A, Saland E, Santos JC, Armengol M, Fernández-Serrano M, Farge T, Cognet G, Simonetta F, Pignon C, Graffeuil A, Mazzotti C, Avet-Loiseau H, Delos O, Bertrand-Michel J, Chedru A, Dembitz V, Gallipoli P, Anstee NS, Loo S, Wei AH, Carroll M, Goubard A, Castellano R, Collette Y, Vergez F, Mansat-De Mas V, Bertoli S, Tavitian S, Picard M, Récher C, Bourges-Abella N, Granat F, Kosmider O, Sujobert P, Colsch B, Joffre C, Stuani L, Swinnen JV, Guillou H, Roué G, Hakim N, Dejean AS, Tsantoulis P, Larrue C, Bouscary D, Tamburini J, Sarry JE. Sabatier M, et al. Among authors: sujobert p. Cancer Discov. 2023 Jul 7;13(7):1720-1747. doi: 10.1158/2159-8290.CD-22-0411. Cancer Discov. 2023. PMID: 37012202
AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.
Grenier A, Poulain L, Mondesir J, Jacquel A, Bosc C, Stuani L, Mouche S, Larrue C, Sahal A, Birsen R, Ghesquier V, Decroocq J, Mazed F, Lambert M, Andrianteranagna M, Viollet B, Auberger P, Lane AA, Sujobert P, Bouscary D, Sarry JE, Tamburini J. Grenier A, et al. Among authors: sujobert p. Cell Rep. 2022 Jan 4;38(1):110197. doi: 10.1016/j.celrep.2021.110197. Cell Rep. 2022. PMID: 34986346 Free article.
VEXAS: where do we stand 2 years later?
Sujobert P, Heiblig M, Jamilloux Y. Sujobert P, et al. Curr Opin Hematol. 2023 Mar 1;30(2):64-69. doi: 10.1097/MOH.0000000000000750. Epub 2022 Dec 30. Curr Opin Hematol. 2023. PMID: 36728604 Review.
From vacuoles to VEXAS.
Heiblig M, Sujobert P. Heiblig M, et al. Among authors: sujobert p. Rheumatology (Oxford). 2023 Dec 1;62(12):3780-3781. doi: 10.1093/rheumatology/kead392. Rheumatology (Oxford). 2023. PMID: 37522863 No abstract available.
[Follicular lymphoma: An update].
Sujobert P, Salles G. Sujobert P, et al. Presse Med. 2019 Jul-Aug;48(7-8 Pt 1):850-858. doi: 10.1016/j.lpm.2019.07.024. Epub 2019 Aug 22. Presse Med. 2019. PMID: 31447334 Review. French.
BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1.
Delage L, Lambert M, Bardel É, Kundlacz C, Chartoire D, Conchon A, Peugnet AL, Gorka L, Auberger P, Jacquel A, Soussain C, Destaing O, Delecluse HJ, Delecluse S, Merabet S, Traverse-Glehen A, Salles G, Bachy E, Billaud M, Ghesquières H, Genestier L, Rouault JP, Sujobert P. Delage L, et al. Among authors: sujobert p. Blood. 2023 Mar 9;141(10):1209-1220. doi: 10.1182/blood.2022016943. Blood. 2023. PMID: 36375119 Free article.
110 results